NSPR InspireMD Inc
35,315
$2.28
$0.02
(0.87%)
| Watchers | 35,315 |
| 52-Wk Low | $1.58 |
| 52-Wk High | $3.85 |
| Market Cap | $56.84M |
| Volume | 8,307.00 |
| 52-Wk High | $3.85 |
| 52-Wk Low | $1.58 |
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobe Newswire • about 2 months ago
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
Share to Feed
TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company's ongoing U.S. Investigational Device...
El mi rcoles, 06 de marzo, InspireMD (NASDAQ:NSPR) publicar su ltimo informe de ganancias. Analiza la noticia con ayuda de Benzinga.
Ingresos netos, ganancias y beneficios por acci n
Las ganancias...
-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard...
Development of SwitchGuard consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class...
TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke...
Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule...